samedan logo
home > pmps > autumn 2019 > a revolution for supply chains
Pharmaceutical Manufacturing and Packing Sourcer

A Revolution for Supply Chains

Information and transparency are key to supply chain efficiency. With the Internet of Things (IoT) the whole world is just a click away. There are different ways to read data. Depending on the application, they are either stationary or mobile. Near Field Communication (NFC)-enabled smartphones can also read out data if data are transferred via NFC works. As soon as readers are able to transfer the data from smart labels to other IoT devices on the same platform via an internet connection, participants in the pharmaceutical supply chain will receive information to their smartphones, tablets, or PCs, which they can evaluate and respond to. This accessible data flow leads to greater transparency, while being tailored to the respective users via a licence management system.

The supply chain for pharmaceuticals is complex, and demands are very high. In these areas, smart labels combined with IoT can save time and money as well as lead to improvements. In the meantime, IoT applications for supply chain management have become a popular investment in many industries. The pharma industry spent $420 million on IoT applications in 2015, and according to a GlobalData forecast, spending will have risen to $2,486 million by 2020. The annual growth rate is expected to reach 43%.

Although the pharma industry already uses IoT applications, it is limited to certain applications, which only take one part of the supply chain into account without being holistically structured.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the Author

In August 2013, Nurdan Citamak joined Faubel Pharma Services and was appointed Director of Business Development and Sales for North America. She graduated in Business Administration from Würzburg-Schweinfurt University, Germany, majoring in International Business from Bond University, Australia. Prior to joining Faubel Pharma Services, Nurdan spent nearly seven years in New York City working in the technology industry where her last position was that of a Director of Operations and Sales. Nurdan’s primary focus is to build awareness for Faubel’s unique capabilities in clinical trial labelling among prospective, existing, and past clients. Furthermore, she is committed to positioning Faubel as its clients’ most trusted business partner, while developing and maintaining substantial client relationships.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Reify Health Raises $220 Million to Eliminate Waiting in Clinical Trials

Reify Health today announced a $220 million Series C funding round led by Coatue Management, joined by ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials


Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement